The Federation of Infection Societies Conference offers sponsors the perfect opportunity to interact with a large cross-section of key stakeholders at the UKs largest annual infection event.

We have bespoke sponsorship packages available which can be tailored to any organisation size and requirements.

Packages can include:

  • Space only and shell scheme booths.
  • Symposium slot and management.
  • Conference attendance for exhibitors and delegates.
  • Inclusion in meeting collateral and web app.
  • Stand design.

Please contact Pharmatologists on +44 (0) 1223 903320 and ask to speak to a member of the exhibitions team.



As a pharmaceutical company, Eumedica ensures the continuity of access to quality & lifesaving therapeutic solutions for healthcare practitioners and patients. We focus on developing and maintaining a diversified range of therapeutic solutions that cover critical unmet medical needs.
The therapeutic areas we focus on are: Infectious Diseases; Cardiovascular Disorders & Hematology; Gastroenterology and Gastro Intestinal Surgery; Central Nervous System – Psychosis management; Anesthesiology.

Hospitals are increasingly encountering unpredictable resistance patterns clinically whilst being faced with the need to minimise broad-spectrum antibiotic use to prevent and reduce antimicrobial resistance. For patients with sepsis, time to effective and optimised therapy is critical.

Accelerate Diagnostics is an in-vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and Healthcare Associated Infections. The company's fully automated ID/AST system, Accelerate Pheno™, and direct from positive blood culture kit, Accelerate PhenoTest™ BC, utilise proprietary molecular and phenotypic detection technologies which have the potential to substantially reduce the time to definitive, actionable antimicrobial susceptibility and MIC results by 1 to 2 days, compared with conventional methods

Rapid ID/AST diagnostics with the Accelerate PhenoTM System allow institutions to:

• Escalate to effective therapy sooner
• Optimise and de-escalate therapy earlier
• Improve patient outcomes and reduce healthcare costs
• Support your antimicrobial stewardship efforts
• Reduce antibiotic resistance
• Decrease C. difficile risk

Cardiome’s mission is to offer patients and healthcare providers innovative therapeutic options that effectively, safely and conveniently manage acute medical conditions to improve health and quality of life
Cardiome has two marketed, in-hospital, cardiology products: BRINAVESS® (vernakalant HCl, IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT® (tirofiban HCl), a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome (ACS). Cardiome also commercializes ESMOCARD® and ESMOCARD LYO® (esmolol hydrochloride), a short-acting beta-blocker used to control rapid heart rate in a number of cardiovascular indications, including supraventricular tachycardia (SVT), on behalf of its partner AOP Orphan Pharma in select European markets, and co-promotes EXEMBOL® (argatroban monohydrate), an anticoagulant indicated for use in patients with heparin induced thrombocytopenia (HIT) type II, with Mitsubishi Tanabe Pharma Europe in the UK.
Cardiome has also licensed: XYDALBA™ (dalbavancin hydrochloride), a second generation, semi-synthetic lipoglycopeptide approved in the EU for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults for select European and Middle Eastern nations and Canada from Allergan; and TREVYENT®, a development stage drug device combination that is under development for Pulmonary Arterial Hypertension (PAH) for Europe, the Middle East and for Canadian markets from SteadyMed Therapeutics.

Curetis’ Unyvero multiplex PCR system is an automated, fast and comprehensive diagnostic tool. We focus on severe infections in hospitalized patients, such as implant and tissue infections, pneumonia, and bloodstream infections. Curetis offers now also a new application for intra-abdominal infections, with rapid detection of relevant pathogens, resistance markers and toxins from various sample types (e.g. aspirates, tissue, and ascites in positive flagged blood cultures).
It allows antibiotic diagnostics and therapy in a targeted and rapid manner. It is a simple and deployable technology that yields results in less than 5 hours.

European Tissue Symposium

ETS is the European Tissue Paper Industry Association. Its members represent the majority of tissue paper producers throughout Europe and around 90% of the total European tissue production. Spreading the message of optimal hand drying after hand washing as a factor to stay healthy and hygienic, is among ETS key priorities. ETS stays updated with the relevant market and technology developments while keeping up with the latest environmental and product safety regulatory requirements. ETS was founded in 1971 and is based in Brussels. For more information www.europeantissue.com.

Nordic Pharma Group

Pathology Group

Synthetic Biologics, Inc. (NYSE American: SYN) is a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients. The Company's lead candidates poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection, overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.